^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | retlirafusp alfa (SHR-1701) (PD-L1 inhibitor, TGF-β R2 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1278P - SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-ß, as first-line therapy for PD-L1+ advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
Published date:
09/13/2021
Excerpt:
Subgroup analysis showed that ORR was 52.0% (95% CI, 31.3-72.2) in the PD-L1 TPS ≥50% population and 37.0% (95% CI, 19.4-57.6) in the <50% population; DCR was 64.0% (95% CI, 42.5-82.0) and 81.5% (95% CI, 61.9-93.7), respectively….SHR-1701 shows encouraging anti-tumor activity in treatment-naive PD-L1+ advanced/metastatic NSCLC pts, compared with the reported historical data of ICI monotherapy. Pts with PD-L1 TPS ≥50% have superior ORR.
Trial ID:
